NICE to review Fabre's Javlor again as comparison with unlicensed drugs deemed unfair
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, failed to act fairly when it compared Pierre Fabre's bladder cancer drug Javlor (vinflunine) with unlicensed comparators not mentioned in NICE's appraisal scope, said the institute's appeal panel.